Cover Image
Market Research Report

Oncology Biosimilars Market (Drug Class - G-CSF, Monoclonal Antibodies, and Hematopoietic Agents; Disease Indication; Distribution Channel) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

Published by Transparency Market Research Product code 562204
Published Content info 183 Pages
Delivery time: 1-2 business days
Price
Back to Top
Oncology Biosimilars Market (Drug Class - G-CSF, Monoclonal Antibodies, and Hematopoietic Agents; Disease Indication; Distribution Channel) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025
Published: September 15, 2017 Content info: 183 Pages
Description

Global Oncology Biosimilars Market: Overview

This report on the oncology biosimilars market analyzes the current and future scenario of the global market. Increasing prevalence of cancer, innovation in the development of new drugs, pipeline analysis, and drug class sales during the forecast period.

The global oncology biosimilars market report contain an elaborate executive summary, which includes following points such as market snapshot that provides information about various segments globally. It also comprise information and data analysis of the country's market with respect to the segments based on drug class, disease indication, distribution channels and regions. A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section. Additionally, the section comprises key molecules, Porters Five Forces Analysis and cancer statistics to help understand the competitive landscape in the market. This section also provides market attractiveness analysis in terms of country and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global oncology biosimilars market.

Global Oncology Biosimilars Market: Market Segmentation

Based on drug class, the market has been segmented into three major drug class such as G-CSF, monoclonal antibody, hematopoietic agents. The market segments have been analyzed based on available approved products, cost-effectiveness. All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

In terms of disease indication - the oncology biosimilars market has been segmented into following segments including breast cancer, non-small cell lung cancer, colorectal cancer, neutropenia, blood cancer and others. . All segments market size and forecast has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report.

As per distribution channels, the oncology biosimilars market has been segmented into three segments including hospital pharmacy, retail pharmacy, and online pharmacy. All market segmentations has been analyzed based on increasing demand for disease treatment. Increased patient hospitalization for the treatment of cancer are driving the market share of hospital pharmacy segment. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2015 to 2025. The report also comprise the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

Geographically, oncology biosimilars market on the basis of region has been segmented into North America, Europe, Asia Pacific and Rest of the World. The market size and forecast for each of these regions have been presented for the period from 2015 to 2025. CAGR for all segments has been presented for the period from 2017 to 2025, 2016 consider as a base year for this report. The report also profiles major key players in the oncology biosimilars market based on various attributes such as company overview, product portfolio, financial overview, business strategies, recent developments and company SWOT analysis.

Global Oncology Biosimilars Market: Competitive Dynamics

Key players for oncology biosimilars market profiled in this report are Celltrion Inc., Pfizer, Inc., Biocon, Sandoz International GmbH (A Novartis Division), Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Apotex Inc. (Apobiologix), Intas Pharmaceuticals Ltd. And BIOCAD.

The Oncology Biosimilars Market has been segmented as follows:

  • Oncology Biosimilars Market, by Drug Class, Revenue (US$ Mn) 2015-2025
  • G-CSF
  • mAb
  • Hematopoetic Agents
  • Oncology Biosimilars Market, by Disease Indication, Revenue (US$ Mn) 2015-2025
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Blood Cancer
  • Leukemia
  • Myeloid Leukemia
  • CLL
  • Others
  • Non-Hodgkin's Lymphoma
  • Colorectal Cancer
  • Neutropenia
  • Others
  • Oncology Biosimilars Market, by Distribution Channel, Revenue (US$ Mn) 2015-2025
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Oncology Biosimilars Market Revenue, by Geography (US$ Bn), 2015-2025
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Rest of the World
  • Mexico
  • Brazil
  • Rest of ROW
Table of Contents

Table of Contents

Section 01 Preface

  • 1.1 Market Definition and Scope
  • 1.2 Research Highlights

Section 02 Assumptions and Research Methodology

  • 2.1 Assumptions & Acronyms Used
  • 2.2 Research Methodology

Section 03 Executive Summary: Global Oncology Biosimilars Market

  • 3.1 Executive Summary
  • 3.2 Market Opportunity Map
  • 3.3 Market Overview
  • 3.4 Key Industry Developments
  • 3.5 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015-2025
  • 3.6 Global Oncology Biosimilars Market Outlook

Section 04 Market Dynamics

  • 4.1 Drivers
  • 4.2 Restraints
  • 4.3 Opportunity
  • 4.4 Key Trends

Section 05 Porter's Five Force Analysis

Section 06 Oncology Biosimilars: Key Molecules

Section 07 Biosimilars Market Snapshot

Section 08 Cancer Statistics

Section 09 Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class

  • 9.1 Introduction & Definition
  • 9.2 Key Findings
  • 9.3 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • 9.4 Market Attractiveness By Drug Class
  • 9.5 Global Oncology Biosimilars Market Forecast, by Drug Class, 2015-2025
    • 9.5.1 G-CSF
    • 9.5.2 Monoclonal Antibody
    • 9.5.3 Hematopoietic Agents
  • 9.6 Global Oncology Biosimilars Market Analysis, by Drug Class, 2015-2025
  • 9.7 Key Trends

Section 10 Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication

  • 10.1 Introduction & Definition
  • 10.2 Key Findings
  • 10.3 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • 10.4 Market Attractiveness By Disease Indication
  • 10.5 Global Oncology Biosimilars Market Forecast, by Disease Indication, 2015-2025
    • 10.5.1 Breast Cancer
    • 10.5.2 Non-Small Cell lung Cancer
    • 10.5.3 Blood Cancer
      • 10.5.3.1 Leukemia
        • 10.5.3.1.1 Myeloid Leukemia
        • 10.5.3.1.2 Chronic Lymphocytic Leukemia
        • 10.5.3.1.3 Others
      • 10.5.3.2 Non-Hodgkin Lymphoma
    • 10.5.4 Colorectal Cancer
    • 10.5.5 Neutropenia
    • 10.5.6 Others
  • 10.6 Global Oncology Biosimilars Market Analysis, by Disease Indication, 2015-2025
  • 10.7 Key Trends

Section 11 Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel

  • 11.1 Introduction & Definition
  • 11.2 Key Findings
  • 11.3 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • 11.4 Market Attractiveness By Distribution Channel
  • 11.5 Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2015-2025
    • 11.5.1 Hospital Pharmacy
    • 11.5.2 Online Pharmacy
    • 11.5.3 Retail Pharmacy
  • 11.6 Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2015-2025
  • 11.7 Key Trends

Section 12 Global Oncology Biosimilars Market Analysis and Forecasts, By Region

  • 12.1 Global Market Scenario
  • 12.2 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025
  • 12.3 Global Oncology Biosimilars Market Attractiveness, by Region, 2017-2025
  • 12.4 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015-2025
    • 12.4.1 North America
    • 12.4.2 Europe
    • 12.4.3 Asia Pacific
    • 12.4.4 Rest of the World

Section 13 North America Oncology Biosimilars Market Analysis and Forecast

  • 13.1 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • 13.2 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • 13.3 North America Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • 13.4 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
    • 13.4.1 U.S.
    • 13.4.2 Canada
  • 13.5 North America Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • 13.6 North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • 13.7 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
    • 13.7.1 G-CSF
    • 13.7.2 Monoclonal Antibody
    • 13.7.3 Hematopoietic Agents
  • 13.8 North America Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • 13.9 North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • 13.10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
    • 13.10.1 Breast Cancer
    • 13.10.2 Non-Small Cell lung Cancer
    • 13.10.3 Blood Cancer
      • 13.10.3.1 Leukemia
        • 13.10.3.1.1 Myeloid Leukemia
        • 13.10.3.1.2 Chronic Lymphocytic Leukemia
        • 13.10.3.1.3 Others
      • 13.10.3.2 Non-Hodgkin Lymphoma
    • 13.10.4 Colorectal Cancer
    • 13.10.5 Neutropenia
    • 13.10.6 Others
  • 13.11 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • 13.12 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • 13.13 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
    • 13.13.1 Hospital Pharmacy
    • 13.13.2 Online Pharmacy
    • 13.13.3 Retail Pharmacy
  • 13.14 Key Trends

Section 14 Europe Oncology Biosimilars Market Analysis and Forecast

  • 14.1 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • 14.2 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • 14.3 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • 14.4 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
    • 14.4.1 U.K.
    • 14.4.2 Germany
    • 14.4.3 France
    • 14.4.4 Italy
    • 14.4.5 Russia
    • 14.4.6 Spain
    • 14.4.7 Rest of Europe
  • 14.5 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • 14.6 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • 14.7 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
    • 14.7.1 G-CSF
    • 14.7.2 Monoclonal Antibody
    • 14.7.3 Hematopoietic Agents
  • 14.8 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • 14.9 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • 14.10 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
    • 14.10.1 Breast Cancer
    • 14.10.2 Non-Small Cell lung Cancer
    • 14.10.3 Blood Cancer
      • 14.10.3.1 Leukemia
        • 14.10.3.1.1 Myeloid Leukemia
        • 14.10.3.1.2 Chronic Lymphocytic Leukemia
        • 14.10.3.1.3 Others
      • 14.10.3.2 Non-Hodgkin Lymphoma
    • 14.10.4 Colorectal Cancer
    • 14.10.5 Neutropenia
    • 14.10.6 Others
  • 14.11 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • 14.12 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • 14.13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
    • 14.13.1 Hospital Pharmacy
    • 14.13.2 Online Pharmacy
    • 14.13.3 Retail Pharmacy
  • 14.14 Key Trends

Section 15 Asia Pacific Oncology Biosimilars Market Analysis and Forecast

  • 15.1 Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • 15.2 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • 15.3 Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • 15.4 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
    • 15.4.1 China
    • 15.4.2 India
    • 15.4.3 Japan
    • 15.4.4 Australia & New Zealand
    • 15.4.5 Rest of Asia Pacific
  • 15.5 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • 15.6 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • 15.7 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
    • 15.7.1 G-CSF
    • 15.7.2 Monoclonal Antibody
    • 15.7.3 Hematopoietic Agents
  • 15.8 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • 15.9 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • 15.10 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
    • 15.10.1 Breast Cancer
    • 15.10.2 Non-Small Cell lung Cancer
    • 15.10.3 Blood Cancer
      • 15.10.3.1 Leukemia
        • 15.10.3.1.1 Myeloid Leukemia
        • 15.10.3.1.2 Chronic Lymphocytic Leukemia
        • 15.10.3.1.3 Others
      • 15.10.3.2 Non-Hodgkin Lymphoma
    • 15.10.4 Colorectal Cancer
    • 15.10.5 Neutropenia
    • 15.10.6 Others
  • 15.11 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • 15.12 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • 15.13 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
    • 15.13.1 Hospital Pharmacy
    • 15.13.2 Online Pharmacy
    • 15.13.3 Retail Pharmacy
  • 15.14 Key Trends

Section 16 Rest of the World Oncology Biosimilars Market Analysis and Forecast

  • 16.1 Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • 16.2 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • 16.3 Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • 16.4 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
    • 16.4.1 Mexico
    • 16.4.2 Brazil
    • 16.4.3 Rest of the World
  • 16.5 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • 16.6 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • 16.7 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
    • 16.7.1 G-CSF
    • 16.7.2 Monoclonal Antibody
    • 16.7.3 Hematopoietic Agents
  • 16.8 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • 16.9 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • 16.10 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
    • 16.10.1 Breast Cancer
    • 16.10.2 Non-Small Cell lung Cancer
    • 16.10.3 Blood Cancer
      • 16.10.3.1 Leukemia
        • 16.10.3.1.1 Myeloid Leukemia
        • 16.10.3.1.2 Chronic Lymphocytic Leukemia
        • 16.10.3.1.3 Others
      • 16.10.3.2 Non-Hodgkin Lymphoma
    • 16.10.4 Colorectal Cancer
    • 16.10.5 Neutropenia
    • 16.10.6 Others
  • 16.11 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • 16.12 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • 16.13 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
    • 16.13.1 Hospital Pharmacy
    • 16.13.2 Online Pharmacy
    • 16.13.3 Retail Pharmacy
  • 16.14 Key Trends

Section 17 Competition Landscape

  • 17.1 Market Player - Competition Matrix (By Tier and Size of companies)
  • 17.2 Market Share Analysis By Company (2016)

Section 18 Company Profiles

  • 18.1 Sandoz International GmbH
    • 18.1.1 Company Details
    • 18.1.2 Business Overview
    • 18.1.3 Financial Overview
    • 18.1.4 Strategic Overview
    • 18.1.5 SWOT Analysis
  • 18.2 Pfizer, Inc.
    • 18.2.1 Company Details
    • 18.2.2 Business Overview
    • 18.2.3 Financial Overview
    • 18.2.4 Strategic Overview
    • 18.2.5 SWOT Analysis
  • 18.3 Celltrion Inc.
    • 18.3.1 Company Details
    • 18.3.2 Business Overview
    • 18.3.3 Financial Overview
    • 18.3.4 Strategic Overview
    • 18.3.5 SWOT Analysis
  • 18.4 Dr. Reddy's Laboratories Ltd.
    • 18.4.1 Company Details
    • 18.4.2 Business Overview
    • 18.4.3 Financial Overview
    • 18.4.4 Strategic Overview
    • 18.4.5 SWOT Analysis
  • 18.5 Biocon
    • 18.5.1 Company Details
    • 18.5.2 Business Overview
    • 18.5.3 Financial Overview
    • 18.5.4 Strategic Overview
    • 18.5.5 SWOT Analysis
  • 18.6 Teva Pharmaceutical Industries Ltd.
    • 18.6.1 Company Details
    • 18.6.2 Business Overview
    • 18.6.3 Financial Overview
    • 18.6.4 Strategic Overview
    • 18.6.5 SWOT Analysis
  • 18.7 STADA Arzneimittel AG
    • 18.7.1 Company Details
    • 18.7.2 Business Overview
    • 18.7.3 Financial Overview
    • 18.7.4 Strategic Overview
    • 18.7.5 SWOT Analysis
  • 18.8 Apotex Inc. (Apobiologix)
    • 18.8.1 Company Details
    • 18.8.2 Business Overview
    • 18.8.3 Financial Overview
    • 18.8.4 Strategic Overview
    • 18.8.5 SWOT Analysis
  • 18.9 Intas Pharmaceuticals Ltd.
    • 18.9.1 Company Details
    • 18.9.2 Business Overview
    • 18.9.3 Financial Overview
    • 18.9.4 Strategic Overview
    • 18.9.5 SWOT Analysis
  • 18.10 BIOCAD
    • 18.10.1 Company Details
    • 18.10.2 Business Overview
    • 18.10.3 Financial Overview
    • 18.10.4 Strategic Overview
    • 18.10.5 SWOT Analysis

List of Tables

  • Table 01 Global Biosimilars Market Snapshot
  • Table 02 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 03 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 04 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2015-2025
  • Table 05 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015-2025
  • Table 06 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 07 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2015-2025
  • Table 08 Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act
  • Table 09 North America Oncology Biosimilars: Pipeline Overview, 2017-2020
  • Table 10 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 11 North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 12 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 13 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 14 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 15 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015-2025
  • Table 16 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015-2025
  • Table 17 Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 18 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 19 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2015-2025
  • Table 20 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 21 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015-2025
  • Table 22 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015-2025
  • Table 23 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025
  • Table 24 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2015-2025
  • Table 25 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2015-2025
  • Table 26 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2015-2025
  • Table 27 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2015-2025
  • Table 28 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2015-2025
  • Table 29 Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2015-2025

List of Figures

  • Fig. 01 Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2015-2025
  • Fig. 02 Global Oncology Biosimilars Market Value Share, by Drug Class (2016)
  • Fig. 03 Global Oncology Biosimilars Market Value Share, by Disease Indication (2016)
  • Fig. 04 Global Oncology Biosimilars Market Value Share, by Distribution Channel (2016)
  • Fig. 05 Global Oncology Biosimilars Market Value Share, by Region (2016)
  • Fig. 06 U.S. Prevalence Share (%), By Cancer Type, 2015
  • Fig. 07 Global Estimation of Cancer, By New Cases & Deaths, 2017
  • Fig. 08 Global Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • Fig. 09 Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • Fig. 10 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2015-2025
  • Fig. 11 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2015-2025
  • Fig. 12 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2015-2025
  • Fig. 13 Global Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • Fig. 14 Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • Fig. 15 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2015-2025
  • Fig. 16 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2015-2025
  • Fig. 17 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2015-2025
  • Fig. 18 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2015-2025
  • Fig. 19 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2015-2025
  • Fig. 20 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015-2025
  • Fig. 21 Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • Fig. 22 Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • Fig. 23 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2015-2025
  • Fig. 24 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2015-2025
  • Fig. 25 Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2015-2025
  • Fig. 26 Global Oncology Biosimilars Market Value Share, by Region, 2017 and 2025
  • Fig. 27 Global Oncology Biosimilars Market Attractiveness, by Region, 2017-2025
  • Fig. 28 North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Fig. 29 North America Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • Fig. 30 North America Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • Fig. 31 North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • Fig. 32 North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • Fig. 33 Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015-2025
  • Fig. 34 Europe Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • Fig. 35 Europe Oncology Biosimilars Market Attractiveness, by Country, 2017-2025
  • Fig. 36 Europe Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • Fig. 37 Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • Fig. 38 Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • Fig. 39 Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • Fig. 40 Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • Fig. 41 Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • Fig. 42 Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Fig. 43 Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • Fig. 44 Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2017-2025
  • Fig. 45 Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • Fig. 46 Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • Fig. 47 Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • Fig. 48 Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • Fig. 49 Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • Fig. 50 Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • Fig. 51 Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015-2025
  • Fig. 52 Rest of the World Oncology Biosimilars Market Value Share, by Country, 2017 and 2025
  • Fig. 53 Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2017-2025
  • Fig. 54 Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2017 and 2025
  • Fig. 55 Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2017-2025
  • Fig. 56 Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2017 and 2025
  • Fig. 57 Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2017-2025
  • Fig. 58 Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2017 and 2025
  • Fig. 59 Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2017-2025
  • Fig. 60 Global Oncology Biosimilars Market Share, by Company, 2016
  • Fig. 61 Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2016 (%)
  • Fig. 62 Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2013-2016
  • Fig. 63 Breakdown of Net Sales of Pfizer, Inc., by Region, 2016 (%)
  • Fig. 64 Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2013-2016
  • Fig. 65 Breakdown of Net Sales of Celltrion Inc., by Business Segments , 2016
  • Fig. 66 Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2013-2016
  • Fig. 67 Breakdown of Net Sales of Dr. Reddy's Laboratories Ltd., by Business Segments, 2016 (%)
  • Fig. 68 Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy's Laboratories Ltd., 2013-2016
  • Fig. 69 Breakdown of Net Sales of Biocon, by Business Segments, 2016 (%)
  • Fig. 70 Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2013-2016
  • Fig. 71 Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2016 (%)
  • Fig. 72 Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2013-2016
  • Fig. 73 Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2016 (%)
  • Fig. 74 Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2013-2016
  • Fig. 75 Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2013-2016
Back to Top